The expansion of resistant subclones due to tumour heterogeneity is now regarded as the major clinical hurdle in patient management.3 About 36%–40% of patients with CRC are characterised by Kras-activating mutation at codons 12, 13 and 61, while 8%–15% present mutations in the Braf gene. This evidence concerns the gene KRAS and colorectal carcinoma.